Clinical trial NCT03418480: HARE-40: HPV Anti-CD40 RNA vaccinE
Official title: Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Human Papilloma Virus Related Carcinoma
Head and Neck Neoplasm
Cervical Neoplasm
Penile Neoplasms Malignant
Unknown Primary Tumors
Lead sponsor: University of Southampton
Sponsor class: OTHER
Collaborators: name: BioNTech SE
First posted: 2018-02-01
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will perform intrapatient dose escalation in patients with previously treated HPV16+ Head \& Neck Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV vaccine.

Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer (head and neck, anogenital, penile, cervical and other) using a single cohort to establish a safe, tolerable and recommended dose of HPV vaccine.

Detailed description: HARE-40 is a phase I/II vaccine dose escalation trial with two arms (Arm 1A and Arm 1B) in which we will test BNT113 as monotherapy. We will undertake a multi-centre phase I, open label trial in patients with previous HPV16+ HNSCC without current clinical evidence of disease (Arm 1A) and in patients with HPV16+ advanced disease (Arm 1B). The HPV16 antigen-specific immune response will be evaluated before and after treatment in circulating blood and, where samples have been collected, in tumour and skin biopsies.

Arms 1A and 1B will escalate BNT113 in each patient (intrapatient dose escalation) up to the specified target dose of the cohort to establish a safe, tolerable and recommended dose of BNT113 in patents who are disease free (Arm 1A) and those with advanced disease (Arm 1B).

Subset of patients in Arm 1B will also be assessed for response to the vaccine in terms of a significant increase of immune cells following BNT113 administration and according to irRECIST1.1 (all 29 patients including the expansion cohort) and other endpoints.

Eligibility criteria: Inclusion Criteria:

Arm 1A:

* Previous HPV16+ head and neck squamous cell carcinoma.
* At least 12 months after completion of treatment.
* Within 5 years of treatment completion.
* Currently no clinical evidence of disease.
* ECOG performance status 0 or 1.

Arm 1B:

* HPV16+ head and neck, cervical, anogenital and penile carcinoma patients with recurrent disease.
* Intention to treat is palliative.
* Patient willing to have repeated tumour biopsies and re-biopsy deemed safe and feasible clinically.
* Tissue samples available confirming HPV16+ disease to send to Central Laboratory.

Exclusion Criteria:

* Patients unable to consent.
* Any patient who has been previously vaccinated in any Arm of the trial.
* \<18 years
* Systemic steroids (prednisolone \>10 mg/day or equivalent) or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry. Replacement steroids for adrenal insufficiency/failure are allowed.
* Major surgery in the preceding three to four weeks, which the patient has not yet recovered from.
* Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection.
* Patients with clinically relevant autoimmune disease will be excluded.
* Patients who are known to be allergic to any of the excipients or constituents of the vaccine
* Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease.
* Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.
* Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.
* Patients who have a positive pregnancy test or who are breast feeding.
* Fertile males or females who are unable or unwilling to use an effective method of birth control (eg. condom with spermicide, diaphragm with spermicide, birth control pills, injections, patches, intrauterine device, or intrauterine hormone-releasing system) during study treatment and until 28 days after patients finish the study treatment.
* Elevated Liver Function Tests - ALT \>3.0 x ULN, AST \>3.0 x ULN, Bilirubin \>3.0 x ULN.
* Any other investigational drug within 28 days or 5 half-lives depending on what gives the longer range before the first treatment of this study

Primary outcomes:
measure: Dose Limiting Toxicity (DLT) according to CTCAE version 4.03 (Arm 1A)
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Southampton
country: United Kingdom
facility: Univeristy Hospitals Southampton NHS Foundation Trust
state: Hampshire
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
affiliation: University of Liverpool
name: Christian Ottensmeier, Prof
role: STUDY_CHAIR
affiliation: University Hospitals Southampton NHS Foundation Trust
name: Ioannis Karydis, Dr
role: PRINCIPAL_INVESTIGATOR
References: